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Abstract
Background: Paw carrageenan induces activation of phosphatidylinositol 3-kinase (PI-3K) and Akt in dorsal horn
neurons in addition to induction of pain behavior. Spinal PI-3K activation is also thought to be required for
inflammation-induced trafficking of GluA1, AMPA receptor subunits, into plasma membranes from cytosol.
Phosphorylation of Akt has a unique time course. It occurs first in the superficial dorsal horn (0.75 h), then soon
dissipates and is followed an hour later by Akt phosphorylation in deeper dorsal horn laminae, primarily lamina V.
Initially, we wished to determine if Akt phosphorylation in the deeper laminae were dependent on the presence of
lamina I, neurokinin receptor bearing projection neurons. As the study progressed, our aims grew to include the
question, whether carrageenan-induced GluA1 subunit trafficking was downstream of Akt phosphorylation.
Results: Rats pretreated with spinal saporin conjugated to a stabilized form of substance P had substantial loss of
neurons with neurokinin 1 receptors throughout their superficial, but not deep dorsal horns. Animals pre-treated
with substance P-saporin exhibited no change in locomotor ability and a small, but significant decrease in
carrageenan-induced mechanical allodynia when compared to animals pre-treated with spinal saporin alone.
Importantly, carrageenan-induced phosphorylation of Akt was blocked, in the substance P-saporin treated group,
throughout the spinal cord grey matter. In marked contrast, carrageenan induced-trafficking of the GluA1 receptor
subunit increased equivalently in both treatment groups.
Conclusions: We infer from these data that 1) phosphorylation of Akt in the deep dorsal horn is dependent on
prior activation of NK1 receptor bearing cells in superficial dorsal horn, and 2) there are parallel spinal intracellular
cascades initiated by the carrageenan injection downstream of PI-3K activation, including one containing Akt and
another involving GluA1 trafficking into neuronal plasma membranes that separately lead to enhanced pain
behavior. These results imply that the two pathways downstream of PI-3K can be activated separately and
therefore should be able to be inhibited independently.
Keywords: spinal sensitization, receptor trafficking, PI-3K, inflammatory pain, AMPA, P-Akt, GluA1, NK1 receptor
Background
Akt is a serine/threonine kinase that plays a pivotal role
in many essential cellular processes including cell survi-
val and apoptosis. Spinal phosphorylation of neuronal
Akt at both the ser 473 and the thr 308 sites occurs fol-
lowing peripheral tissue injury; this can be observed
throughout the superficial dorsal horn [1-4], but also is
elicited prominently in lateral lamina V and in a-motor
n e u r o n s[ 3 ] .T h i si sat o p i co fi n t e r e s t ,a ss p i n a lb l o c k -
ade of Akt phosphorylation (P-Akt) or phosphatidylino-
sitol 3-kinase (PI-3K), its upstream activator, results in
amelioration of injury-induced pain behavior [1,2,4,5].
More generally, phosphorylation of Akt is held to be an
indicator of neuronal, nociceptor in particular, activation
and sensitization [6]. Our recent investigation of this
phenomenon using immunohistochemistry for P-Akt
(ser473) following carrageenan injection into the plantar
hindpaw, revealed an unexpected time course of P-Akt
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At 0.75 h after paw injection, the number of P-Akt posi-
tive neurons increased substantially in the superficial
dorsal horn compared to basal levels with no change
observed in laminae IV or V. In stark contrast, at 2
hours after paw injection, we observed no remaining
Akt phosphorylation in the superficial laminae and
development of a pronounced increase in P-Akt positive
neurons in lamina V. Equally surprising, examination of
the ventral horn revealed a small increase in P-Akt in
the a-motor neurons at 0.75 h, which had largely dissi-
pated by the 2.0 h time point. These last results are par-
allel to, and coincident with, results seen in superficial
dorsal horn. The present study re-examined this laminar
specific time course in the presence and absence of
spinal pre-treatment with stabilized substance P-conju-
gated to saporin (SSP-Sap). This agent, when used at
the appropriate dose and duration after administration,
is a specific neurotoxin, which kills neurons with neuro-
kinin 1 receptors in the superficial but not the deeper
laminae of the dorsal horn [7,8]. The purpose of these
experiments was to ascertain if loss of these superficial
neurons was sufficient to prevent phosphorylation of
Akt induced by paw carrageenan in laminae V and IX.
Our initial thought was that activation of NK1 positive
projection neurons in superficial dorsal horn [1,9] trig-
gered a bulbospinal pathway, which in turn, activated
the deep dorsal horn neurons of lamina V [10,11].
Blockade of P-Akt in motor horn neurons was postu-
lated to occur via local actions of the NK1 positive pro-
jection neurons through their axon collaterals [12] or
polysynaptically via NK1 positive excitatory interneurons
in the superficial dorsal horn [13,14]. Parallel experi-
ments were conducted to determine the effects of SSP-
Sap pretreatment (loss of superficial dorsal horn NK1
receptor bearing neurons) on paw carrageenan-induced
pain behavior and increases in plasma membrane-asso-
ciated GluA1 in dorsal horn, an index of increased
AMPA receptor trafficking, which is thought to contri-
bute to spinal long- term potentiation and sensitized
pain states [15].
In short, our results indicate that loss of NK1 positive
neurons in superficial dorsal horn, including presump-
tive nociceptive projection neurons, substantially blocks
carrageenan-induced P-Akt expression in all laminae.
Surprisingly, pre-treatment with SSP-Sap had only a
modest anti-allodynic effect on enhanced mechanical
withdrawal thresholds and no effect on carrageenan-
induced GluA1 subunit increases in plasma membrane.
Results
NK1 receptor
Otherwise naïve animals pre-treated with BSA (one ser-
ies only) or Sap (two series of experiments) exhibited
NK1 receptor positive structures throughout the superfi-
cial dorsal horn as well as in laminae IV and V (Figure
1A), as previously published by others [16,17]. There
appeared to be a higher concentration of NK1 staining
in the lateral half of the grey matter. This lateral ten-
dency was more pronounced in the deeper laminae. In
the ventral horn, NK1 staining was clearly higher in
motor neurons than in the surrounding neuropil. This
observation was not quantified, however, NK1 receptor
staining on motor neurons has been shown previously
by Basbaum and several collaborators [16,18]. There
were no obvious differences between the BSA and Sap
treated animals (Figure 1C). In contrast, ten days after
intrathecal SSP-Sap administration, immunohistochem-
istry revealed depletion of NK1-like receptor in laminae
I-III compared to levels observed in Sap or BSA pre-
treated animals (Figure 1B, C). Levels of pixel intensity
in arbitrary units were reduced on average by 68.3%; p ≤
0.01 (Figure 1C). Few large NK1 receptor positive neu-
rons were seen in laminae I-III and the remaining
receptor appeared to be located in small cells or scat-
tered in the neuropil. Levels of NK1 receptor in the dee-
per dorsal horn laminae showed no significant difference
among the three pretreatment groups; there was on
average a 5.08% decrease compared to the combination
of BSA and Sap pre-treated animals (Figure 1D). NK1
staining intensity on motor neurons appeared to be
unchanged in all but one animal, which had developed
motor deficits and was eliminated from the study prior
to immunohistochemical analysis. There were no
obvious differences in NeuN staining among the groups
at any laminar level (not shown).
Behavior
Locomotor ability
Animals in the SSP-Sap pretreatment group were indis-
tinguishable from untreated animals in all aspects of
their general behavior. Loss of NK1 receptor bearing
neurons in the superficial do r s a lh o r nd i dn o tr e s u l ti n
motor deficits as determined by rotarod testing; p ≤
0.58. Animals in the Sap pretreatment group had mean
times of 104.7 s ± 12.4 on the rotarod before falling off,
while the average for animals pretreated with SSP-Sap
was 114.7s ± 12.0 (Figure 2A).
Mechanical withdrawal threshold
Prior to carrageenan injection, mechanical withdrawal
thresholds were the same in Sap (control) and SSP-Sap
pretreated rats. These data are consistent with electro-
physiological findings reported by Suzuki et al. [10],
who found that stimulation of skin with von Frey hairs
having 1-15 g bending force produced equivalent num-
bers of action potentials in lamina V wide dynamic
range neurons recorded from both saline and substance
P -saporin pretreated animals prior to peripheral tissue
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Page 2 of 11Figure 1 Micrographs illustrate typical lumbar dorsal horn staining for NK1 receptor in animals pretreated with spinal Sap (A) or SSP-
Sap (B) 10 days prior to perfusion. The majority of the NK1R staining, including staining of almost all large somata, is missing in superficial
dorsal horn after the SSP-Sap pretreatment. Size marker = 100 μm. C. Graphs show mean pixel count in laminae I-III and in laminae IV-V
following the different spinal pretreatments. *** = p ≤ 0.0001 N = 3 for BSA pretreatment and 8 each for Sap and SSP-Sap.
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Figure 2 A. Pretreatment with Sap or SSP-Sap made no difference in time spent on an accelerating rotarod before falling off. B. Rats
pretreated with Sap developed a profound mechanical allodynia following carrageenan as shown by their 50% probability withdrawal threshold
to von Frey filaments. Animals pretreated with SSP-Sap also developed hyperalgesia, but thresholds were elevated compared to SAP pretreated
animals at all timepoints except at 2 h post-carrageenan. C. Area under the curve for the two treatments indicates that SSP-Sap reduced
allodynia integrated over the entire time period. ** = p ≤ 0.001
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siological data from others indicate that responses to
mechanical stimulation of the paw in the innocuous
range do not significantly differ in the SP- or SSP-Sap
pretreated animals from those seen in control animals.
Following intraplantar carrageenan, injected paws exhib-
ited extreme inflammation, up to and including the
ankle, regardless of intrathecal pretreatment. In rats pre-
treated with Sap, carrageenan evoked mechanical allody-
nia was comparable to that seen in previous
experiments without pretreatment. Decreases in thresh-
old were prominent within 1 h and remained at this pla-
teau for the remainder of the observation period; p ≤
0.0001, repeated measures ANOVA (Figure 2B). Thresh-
olds at all time points were significantly less than base-
line (p ≤ 0.0001, Bonferroni multiple comparison test).
Although mechanical withdrawal thresholds of rats pre-
treated with SSP-SAP also decreased compared to base-
line following paw carrageenan injection (p ≤ 0.0001),
the decrease was significantly less than in control Sap
animals. The area under the curve for each of the two
groups is illustrated in Figure 2C(p ≤ 0.01). Thus, SSP-
Sap and the resultant loss of NK1 receptor expressing
neurons in superficial dorsal horn diminished, but did
not eliminate carrageenan-induced pain behavior.
P-Akt
The carrageenan-induced pattern of P-Akt immunoreac-
tivity in BSA (not shown) and Sap pretreated animals
was the same as previously reported in untreated ani-
mals [3]. Forty-five min after intraplantar carrageenan,
we observed the majority of P-Akt positive neurons in
the superficial dorsal horn (Figure 3A). All of the sec-
tions showed prominent staining in the lateral tissue,
although not in extreme lateral tip. There seemed to be
more variability in the relative staining intensity of the
P-Akt in the medial superficial dorsal horn. At this
time, carrageenan also induced P-Akt in a substantial
number of motor neurons (Figure 3C), with fewer posi-
tive neurons in lamina IV and the lowest density in
lamina V (Figure 3A). When tissue was harvested 2 h
post carrageenan injection (Figure 3B and 3G), P-Akt
positive neurons were rarely seen in the superficial dor-
sal horn (p ≤ 0.001; compared to 0.75 h) and staining of
motor neurons was reduced (p ≤ 0.05; compared to 0.75
h). In contrast, the number of immunopositive neurons
in lamina IV-V increased more than 400% (p ≤ 0.001).
These time-dependent peaks in carrageenan induced P-
Akt immunopositive neurons in superficial dorsal horn
and in motor neurons at 0.75 h, and in laminae IV-V at
2 hours were similar to those observed in our previous
study with no intrathecal pretreatment and bilateral car-
rageenan injections [3].
Following pretreatment with SSP-Sap, the number of
P-Akt positive neurons observed at 0.75 h in the
superficial dorsal horn and at 2 h in laminae IV and V
were significantly reduced compared to those seen in
the Sap pretreated animals (Figure 3D-G). Although the
difference in number of stained motor neurons between
the two different pre-treatment paradigms did not reach
significance, carrageenan no longer elicited a significant
increase in staining (Figure 3G). Under basal conditions,
with no carrageenan, we previously observed infrequent
P-Akt positive neurons in the superficial dorsal horn
and an average of 2-3 P-Akt positive neurons in laminae
IV-V; thus, SSP-Sap pretreatment prevented all of the
carrageenan-induced Akt activation in the deep dorsal
horn and virtually all of that seen in superficial dorsal
horn.
Membrane GluA1
As we have seen previously in naïve animals, paw carra-
geenan in control Sap pretreated animals, elicited
approximately a doubling of plasma membrane GluA1;
p ≤ 0.05, N = 3-5 (Figure 4). In SSP-Sap pretreated ani-
mals, carrageenan also elicited an increase in plasma
membrane GluA1; p ≤ 0.05, N = 3-5. This percent
increase in membrane GluA1 was no different than that
observed in the Sap controls; p > 0.05. Given that the
SSP-Sap animals had substantially less P-Akt, these data
suggest that paw carrageenan-induced trafficking into
the membrane is Akt independent.
Discussion
The most striking findings of this study are that pre-
treatment with SSP-Sap: 1) blocked the carrageenan-
induced expression of P-Akt throughout the dorsal horn
as well as in a-motor neurons; 2) significantly reduced,
but did not eliminate carrageenan-induced mechanical
allodynia and 3) did not decrease carrageenan-induced
increases of GluA1 trafficking into the membrane.
Taken together we infer from these data that 1) phos-
phorylation of Akt in the deep dorsal horn is dependent
on prior activation of NK1 receptor bearing cells in the
superficial dorsal horn, 2) there are parallel spinal intra-
cellular cascades initiated by the carrageenan injection,
including one containing P-Akt, that separately lead to
enhanced pain behavior, and 3) carrageenan-induced
GluA1 trafficking into the plasma membrane and the
pain behavior resulting from this process are not down-
stream of P-Akt (Figure 5).
Immunohistochemical data indicate that the SSP-Sap
treatment was successful in substantially reducing NK1
staining in the superficial dorsal horn. Lamina I neuro-
nal populations with high densities of NK1 receptor
include approximately 80 percent or more of all spinor-
eticular, spinoparabrachial and spinothalamic tract neu-
rons [9,19-21]. It is unlikely that there was significant
loss of NK1 receptor expressing neurons in deeper lami-
nae. Although Nichols et al. demonstrated measurable
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Page 4 of 11Figure 3 A-C Spinal cords from Sap pre-treated animals. A shows dorsal horn from rat perfused 0.75 h post carrageenan, green = P-Akt,
most of the P-Akt is in the superficial dorsal horn. Calibration mark = 100 μm and is the same for all dorsal horn pictures. The middle panel (B)
shows dorsal horn from an animal perfused 2.0 h post carrageenan. Note that P-Akt activity has shifted from the superficial to the deeper
laminae. The bottom panel (C) shows P-Akt in ventral horn 0.75 h post-carrageenan. Calibration mark = 50 μ. Pretreatment with SSP-Sap reduces
carrageenan-induced P-Akt in superficial dorsal horn (D) and ventral horn (F) at 0.75 h and in laminae IV and V at 2 h (E). G Mean number of P-
Akt positive neurons ± SEM counted in each area under the two conditions, Sap and SSP-Sap pretreatment. Cells were counted only if the P-Akt
was co-localized with NeuN (not shown). * p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001 Pictures (A-F) and counts (G) are from sides ipsilateral to the
injection.
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Page 5 of 11loss of lamina III neurons at 30 days after SP-Sap and
throughout the dorsal horn at 100 and 200 days post
infusion of the toxin [22]; Wiley et al., using the SSP-
Sap at the same dose and survival time (seven days) that
we employed, demonstrated a selective loss of lamina I
neurons with no neuronal decrease in laminae III-VI or
× [7]. An exciting recent paper from Todd’sg r o u p
describes two populations of NK1 receptor bearing pro-
jection neurons, larger neurons with GluA4 AMPA
receptor subunits and medium sized neurons that were
positive for GluA1, rather than GluA4 [23]. They also
identified a third population of smaller neurons, having
lower NK1 receptor densities, that were not projection
cells [21]. Neurons of this class, which numerically is
t h el a r g e s to ft h et h r e e ,a r en o tG A B A e r g i ci nl a m i n aI
[24], thus a large number of them are presumptive exci-
tatory interneurons. Al Ghamdi and colleagues have
posited that due to their low level of receptor, this inter-
neuronal population may not be killed by spinal saporin
linked to substance P. This hypothesis suggests that the
roughly 30% of the NK1 immunoreactivity, as deter-
mined by pixel count, that remained in the superficial
dorsal horn after SSP-Sap pretreatment could be attribu-
ted to retention of this interneuronal population. Impor-
tantly, loss of NK1 receptor bearing neurons in the
superficial dorsal horn prevented not only carrageenan-
induced P-Akt in superficial dorsal horn, but also
blocked induction of P-Akt in the deeper dorsal horn
lamina and reduced it in the motor neurons. Since
development of P-Akt in superficial dorsal horn and
motor neurons has the same time course, we originally
thought that loss of presumptive motor neuron sensiti-
zation was due to loss of excitatory interneurons in the
superficial dorsal horn that are part of the flexion reflex
arc. However, if, as hypothesized above, those neurons
are retained, the carrageenan-induced induction of
motor neuron P-Akt must be due to a different mechan-
ism. The motor neuron response could be triggered via
local collaterals of the NK1 receptor bearing projection
n e u r o n s[ 1 2 ] ( a c t i n ga saf i r s t step); alternatively, the
motor neurons could be activated by a spino-bulbo-
spinal loop, which uses the projection neuron as the
ascending leg. Our data does not allow us to decide
between these alternatives. The pronounced time differ-
ence observed between appearance of P-Akt in superfi-
cial and deeper dorsal horn laminae could be due to
involvement of different signal transduction cascades in
different neuronal populations. These neurons could
possess different time courses, leading to the same end-
point (P-Akt). Alternatively, induced P-Akt in deeper
laminae could be due to a complex spino-bulbo-spinal
pathway, which has been observed by others to be
involved in peripheral tissue or nerve injury-induced
sensitization of deep dorsal horn neurons [20,22,25,26]
or to some combination of the two. Further experiments
will have to be undertaken to delineate the difference in
induction time.
Our rotarod data indicate that loss of projection neu-
rons in the superficial laminae does not decrease loco-
motor activity, thus local proprioceptive circuitry
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intraplantar carrageenan elicited a doubling of GluA1 subunits
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in the percent increase between the treatments. Representative
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Figure 5 Schematic of hypothesis: Inflammation induced
release of spinal TNF activates PI-3K probably via TNF receptor
1. PI-3K leads to phosphorylation of Akt, both directly and indirectly
through PDK1. P-Akt activates signal transduction cascades leading
to central sensitization. PDK1 also activates PKA, which
phosphorylates GluA1 at ser 845. Phosphorylation at this site lowers
the energy required for GluA1 insertion into the plasma membrane
as part of a functional AMPA receptor. Increased AMPA receptor
density, especially AMPA receptors enriched with GluA1 rather than
GluA2, contributes to spinal long term potentiation and pain
behavior. Despite the fact that they both are initiated through a PI-
3K linkage, phosphorylation of Akt and GluA1 trafficking seem to be
independent of one another.
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Page 6 of 11appears to be intact. This is consistent with the reported
lack of change in overall behavior [22] and maintained
flinching frequency in the phase 1 formalin test [10] fol-
lowing spinal administration of substance P-Sap.
The overall decrease of enhanced pain behavior seen
in Figure 2B was modest compared to the loss of spinal
sensitization seen following similar SP-Sap pre-treat-
ment prior to intradermal capsaicin, which substantially
eliminates mechanical and thermal hyperalgesia after
capsaicin injection into the paw [8,27]. Phase 2 activity
of the formalin test is also substantially reduced by both
SP-Sap and SSP-Sap pretreatments [7,10,22].
However, at several timepoints following injection of
complete Freund’s adjuvant (CFA) [10] and carrageenan
[22], these same investigators observed a substance P-
saporin associated attenuation rather than obliteration
of inflammation-induced mechanical allodynia that was
more similar to our results. Differing degrees of attenua-
tion may represent differences in sensitizing mechan-
isms, perhaps involving multiple redundant pathways
between the more slowly developing, longer lasting
inflammatory models such as carrageenan and CFA vs.
capsaicin or formalin injection, which produce a more
brief barrage of afferent drive. Other reasons for greater
residual allodynia in our study may include greater mag-
nitude of allodynia in our control animals or variations
in testing protocols. The greatest loss of pain behavior
was seen at the first hour post-carrageenan when the
model was in transition between pain behavior due to
trauma secondary to the injection and pain behavior
secondary to peripheral inflammatory processes [28].
In marked contrast to the significant residual carra-
geenan-induced mechanical allodynia seen after pre-
treatment with the SSP-Sap, our data indicate that the
pathway leading to Akt activation was profoundly sup-
pressed by the chemical lesion in the superficial dorsal
horn. Akt is a second messenger downstream of phos-
phatidylinositol 3-kinase (PI-3K) and mediates many of
its survival functions through phosphorylation and regu-
lation of transcription factors including nuclear-factor-
kappa B, mTor, various caspases and GSK3. Antagonism
of the PI3K/Akt pathway at the level of the spinal cord
and dorsal root ganglia is thought to be anti-hyperalge-
sic. Spinal pretreatment with various Akt inhibitors
attenuates the phase 2 formalin response [1] and ther-
mal hyperalgesia and mechanical allodynia resulting
from spinal nerve ligation [4]. Willis’s group has shown
that Akt inhibition results in total blockade of mechani-
cal hyperalgesia induced by intradermal capsaicin [2],
again pointing to potential differences in magnitude
between acute capsaicin responses and longer term
inflammatory conditions. Importantly, our group has
reported only attenuation of carrageenan-induced allo-
dynia in animals pretreated with spinal Akt inhibitors
[1,3]. However, despite these data implicating Akt in
spinal sensitization, a recent study demonstrated that
morphine-mediated peripheral analgesia is Akt mediated
[29].
Prior to insertion into the plasma membrane, GluA1
subunits of AMPA receptors, contained within cytosolic
endosoms, are phosphorylated by PKA at ser 845. In the
hippocampus, this process appears to be necessary, but
not sufficient for extrasynaptic membrane insertion of
GluA1 containing AMPA receptors [30-32]. Other stu-
dies have shown that spinal inhibition of PKA blocks
GluA1 trafficking in the dorsal horn following capsaicin
injections [33]. Our previous work indicates that spinal
pretreatment with the TNF antagonist etanercept blocks
carrageenan-induced increases in P-Akt, P-GluA1
ser845 and trafficking of GluA1 into the plasma mem-
brane [3]. We hypothesized at the time 1) that TNF act-
ing through one of its receptors led to activation of
PI3K and Akt and 2) that PKA phosphorylation of
GluA1ser845 and trafficking into the membrane was
downstream not only of the spinal TNF release, but also
of the PI3K and Akt activation. However, this hypothesis
requires that activation of PKA is downstream of P-Akt.
We have not seen clear proof of this linkage in the lit-
erature. However, we have seen evidence that PDK1,
which is upstream of P- Akt can activate or prime PKA,
as well as PKC [34-36]. Thus, in light of our present
data we believe that GluA1 receptor trafficking is inde-
pendent of Akt (Figure 5).
Using neuronal tracing and post-embedding immuno-
gold labeling to examine primary afferent fiber synapses
in the superficial dorsal horn, Larsson and Broman [37]
have shown that following noxious stimulation, the
majority of AMPA receptors with enriched GluA1 subu-
nit composition were post-synaptic to non-peptidergic
primary afferent C fibers with a far less prominent
increase in GluA1 postsynaptic to the peptidergic pri-
mary afferent fibers. This is in keeping with the lack of
correspondence that we observed between loss of NK1
receptor-bearing neurons and increased translocation of
GluA1 at the plasma membrane. It also brings up the
possibility that rather than two parallel signal transduc-
tion cascades in the same neurons, different populations
of neurons exhibit Akt phosphorylation and GluA1 traf-
ficking in response to intraplantar carrageenan.
Conclusions
We infer from these data that 1) phosphorylation of Akt in
the deep dorsal horn is dependent on prior activation of
NK1 receptor bearing cells in lamina I, 2) there are parallel
spinal intracellular cascades or separate neuron pathways
initiated by the carrageenan injection. One includes Akt
phosphorylation and a second is Akt independent and
ends in GluA1 movement into plasma membranes.
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Animals
Male Holtzman rats (Harlan Industries, Indianapolis, IN,
USA) weighing 250-300 g were housed in pairs on a 12-
h light/dark cycle with controlled temperature and free
access to food and water. Efforts were made to minimize
animal discomfort and reduce numbers of animals used.
All experiments were carried out according to the
National Institute of Health Guide for the Care and Use
of Laboratory Animals, and the Institutional Animal
Care and Use Committee of the University of California,
San Diego approved this study protocol.
In preparation for the actual experiments, rats were
anesthetized with isoflurane (4% for induction, 2% for
maintenance) and a polyethylene-5 (PE5) catheter
(Scientific Commodities, Inc., Lake Havasu City, AZ)
was inserted into the intrathecal space caudally from
the cisterna magna and ending over the thoraco-lum-
bar junction. Saporin or 100 ng of [Sar9Met(O2)11]
substance P coupled to saporin (SSP-Sap, Advanced
Targeting Systems, San Diego, CA) was injected
through the catheter in a 10 μl volume, followed by 10
μl of saline, and the catheter then remained in place
for 30 min before its removal. The addition of Sar9-
Met(O2)11 to substance P conjugated to saporin
makes the agent more stable and potent than sub-
s t a n c ePa l o n eb o u n dt os a p o r i n .T h ed o s e ,i n j e c t i o n
volume and pre-treatment interval that we used were
based on Wiley et al., who observed no loss of lumbar
dorsal horn neurons expressing the NK1 receptor in
deeper laminae and prominent loss of NK1 receptor in
lamina I [7]. In one set of control animals intended for
histological analysis, our first pre-treatment injection
was 10 μl bovine serum albumin (BSA) rather than
Sap or SSP-Sap.
The skin incision overlying the dural entry site was
closed with 3-0 silk suture and animals were allowed
to recover in their home cages for 10-14 days. Rats
received a 5 mL subcutaneous injection of Lactated
Ringer’s solution (Baxter HealthCare Corporation,
Deerfield, IL, USA) containing carprofen (5 mg/kg; Pfi-
zer Animal Health, New York, NY, USA) for potential
pain relief immediately after surgery and again on the
following day. After recovery from anesthesia, any rats
with motor or postural deficits (less than 5%) were
immediately sacrificed by inhalation of carbon dioxide
followed by bilateral pneumothorax. Interestingly, one
animal developed motor weakness seven days post
injection; the animal was perfused at this time and
lumbar spinal cord processed for NK1-like immunor-
eactivity. Histological analysis showed a prominent
loss of NK1 staining in the ventral horn (data not
shown). Data from this animal were not included in
any analysis.
Carrageenan-induced inflammation
Carrageenan (degraded l-Carrageenan, Wako Pure Che-
mical Industries, Japan) was dissolved in saline to form
a 2% solution and stored at room temperature for 24 h;
100 μl of this solution was injected subcutaneously into
the center of the ventral surface of the left hind paw
under light isoflurane anesthesia using a 30 g needle.
Carrageenan injection was unilateral.
Behavioral testing
Locomotor testing
Animals were trained on an accelerating rotarod
(Columbus Instruments, Columbus, OH, USA). Training
consisted of two or more 1 min trials at 4 rpm on each
of two sequential days. Once animals would stay on the
device for 60 s, they had two sessions with the rod
accelerating at 0.1 rpm/s. On day three, animals were
placed on the rod for several seconds at 4 rpm before
acceleration began. The average of three measures (30
min or more apart) was taken; animals that did not fall
off or jump were taken off of the rod 180 s after the
acceleration began. The person performing the beha-
vioral testing was blinded as to the chemical nature (Sap
or SSP-Sap) of the pre-treatment.
Mechanical Threshold
Animals were acclimated to the testing room and appa-
ratus (one hour in their home cage and 1 hour in the
test chamber) on three separate days prior to data col-
lection. On the day of the experiment, rats were brought
to the testing room and left in their cages for at least 30
min and then placed in individual Plexiglas test cham-
bers with wire mesh floors for another 30 min prior to
testing. Mechanical withdrawal thresholds were assessed
with a set of von Frey filaments (Stoelting, Wood Dale,
IL, USA) having buckling forces between 0.41 and 15.2
g. The paradigm was based on the up-down test [38] to
obtain the 50% probability withdrawal threshold. Fila-
ments were applied perpendicularly to the plantar sur-
face of the hindpaw through the wire mesh floor until
the filament was just slightly bent. Each application was
maintained for 6 seconds or until the animal rapidly
lifted or licked the hind paw; both paws were tested.
A n yr a tw i t ham e a no rl e f tp a wb a s a lw i t h d r a w a l
threshold below 10 g was excluded from the study.
After carrageenan injection into the area on the left
paw, which had been tested with the von Frey filaments,
withdrawal thresholds were re-determined at 1-hour
intervals for a 4-hour period. The person performing
the behavioral testing was blinded as to the chemical
nature (Sap or SSP-Sap) of the pre-treatment.
Immunohistochemistry
At specified time points following carrageenan injection,
rats were anesthetized with isoflurane and transcardially
perfused with cold heparinized 0.9% saline containing
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paraformaldahyde in 0.1 M phosphate buffer. Spinal
cords were removed and post-fixed in perfusate for 6 h
and transferred, first to 20% sucrose for 12-24 hs and
then to 30% sucrose for cryoprotection. Tissue was kept
at 4°C. The fixed lumbar enlargements were embedded
in O.C.T. compound (Tissue-Tek, Torrance, CA, USA)
snap frozen, and transverse sections (20 μm) from L4-
L5 were cut on a Leica CM 1800 cryostat. Sections were
mounted on Superfrost Plus glass slides (Fisher Scienti-
fic, Pittsburgh, PA, USA) and double labeled with rabbit
monoclonal anti-P-Akt ser 473 (1:200; Cell Signalling,
Danvers, MA, USA) or polyclonal anti-NK1 (1:3,000;
Advanced Targeting Systems, San Diego, CA, USA) and
the cell marker, mouse anti-Neu N (neurons, 1:500;
Millipore, Temecula, CA, USA). Reported results were
observed in 8 animals each following pretreatment with
Sap and SSP-Sap and in 3 animals with BSA pre-treat-
ment; clearly P-Akt immunopositive neurons were
counted, under blinded conditions, within the bound-
aries of laminae I-III, lamina IV-V and the ventral horn.
Cells were counted only if there was a clearly visible
nucleus and double labelingw i t hN e u N .V e n t r a lh o r n
cells were only counted if they had minimum somal dia-
meters of 25 μm and, thus, were presumptive a-motor
neurons. Binding sites were visualized with species
matched goat anti-rabbit secondary antibody conjugated
with Alexa Fluor 488 (1:500; Invitrogen, Carlsbad, CA,
USA) or goat anti-mouse antibody conjugated with
Alexa Fluor 594 (1:500, Invitrogen). Equivalent dilutions
of normal rabbit or mouse IgG were substituted for pri-
mary antibodies as a control for non-specific staining.
Images were captured with a fluorescence microscope
(Olympus, Melville, NY, USA) at 10-60× with an
attached Olympus America digital camera linked to a
computer. Single channel fluorescent images were
acquired using Image-Pro Plus software (Media Cyber-
netics, Bethesda, MD USA). NK1 receptor staining was
quantified as density in standardized boxes centered in
central lamina I-II and lateral lamina V using the satu-
rated fluorescent images. Box placement was performed
by an investigator who was unaware of the agent used
for pre-treatment. For presentation, images were con-
verted to grayscale, and inverted in pixel intensity (i.e.,
white to black; with dark pixels representing positive
labeling; Figure 1). Multi-channel green-red fluorescent
images were acquired and merged to count neurons
that were positive for P-Akt labeling. The red NeuN
channel was eliminated for the final image (Figure 3).
Subcellular membrane fractionation and Western Blots
C r u d ep l a s m am e m b r a n ef r a c t i o nG l u R 1w a sm e a s u r e d
in whole cell homogenates obtained 1 h after paw injec-
tion with carrageenan. Animals were deeply anesthestized
with isoflurane (5%), decapitated and the spinal cord was
extruded with cold saline. After dissecting a 1 cm length
of lumbar enlargement (L2-L5), the dorsal quadrant ipsi-
lateral to the carrageenan injection was harvested and
immediately frozen with dry ice and stored at -70°C. Fro-
zen tissue was placed in a dounce homogenizer in 3 ml
of hypotonic buffer containing protease and phosphatase
inhibitors (Sigma, St. Louis, MO, USA),1m MN a H C O 3
in H2O and homogenized. The homogenate was allowed
to rest on ice for 10 min and was then centrifuged at
12,000 rcf for 10 min at 4°C, and the supernatant
removed. This (S1) was then centrifuged at 21,600 rcf for
30 min at 4°C. The resulting supernatant (S2) was then
subjected to 150,000 rpm at 4°C for 2 h and the resulting
pellet containing the plasma membranes was washed in 4
ml hypotonic buffer and centrifuged again at 150,000 rcf
for 2 hr. The final pellet was resuspended in 50 μls t a n -
dard extraction buffer (50 mM Tris, pH 7.4; 150 mM
N a C l ;1m ME D T A ,p H8 ;0 . 5 %T r i t o nX - 1 0 0w i t hp r o -
tease and phosphatase inhibitors).
Protein concentration of this final suspension was
determined using a bicinchoninic acid (BCA) kit (Pierce
Biotechnology Inc., Rockford, IL, USA). Equivalent
amounts (15 μg) of protein from each sample were
loaded into a Nu-PAGE 4-12% Bis-Tris Gel (Invitrogen,
Carlsbad, CA, USA) in MOPS running buffer and trans-
ferred onto a nitrocellulose membrane. The membrane
was blocked with 5% nonfat milk in Tris-HCl buffer
containing 0.1% Tween 20, pH 7.4 (TBS-T) for 1 hour
at room temperature and then incubated overnight at 4°
C with rabbit anti-GluA1 (1:1000; Millipore, Temecula,
CA). The membrane was washed with TBS-T and then
incubated with goat anti-rabbit HRP (horseradish perox-
idase)-linked secondary antibody (Cell Signalling) for 1
hour on the next day. After incubation the membrane
was exposed to SuperSignal West Femto substrate
(Pierce Biotechnology, Inc.) to enhance the signal. Fol-
lowing exposure to X-ray film, membranes were
stripped and reprocessed for N-cadherin, a marker for
plasma membranes (rabbit anti-N-cadherin,1:1,000; Cell
Signalling) as a loading control. Immunoblots were
scanned and densitometric analysis performed using
ImageQuant (Amersham Biosciences, Piscataway, NJ,
USA). Immunoblot density was normalized to controls
run on the same gel.
Statistical Analysis
Behavioral data were expressed as mean ± S.E.M. An
unpaired t-test was used to compare rotarod duration
between the Sap and the SSP-Sap animals. Mechanical
withdrawal threshold was also expressed as area beneath
t h ec u r v ea n da l s oc o m p a r e du s i n gu n p a i r e dt - t e s t s .
Withdrawal thresholds from each pretreatment were
analyzed using an ANOVA for repeated measures.
Membrane fraction GluA1 from carrageenan-injected
animals was normalized to the mean of the appropriate
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rageenan-injected animals using an unpaired t-test. Cell
counts and pixel density were compared using unpaired
t-tests. The percentage loss of NK1 staining was calcu-
lated by taking the staining intensity in the SSP-Sap ani-
mals divided by that of the control animals and
multiplying by 100. That gave us the % remaining stain-
ing density. To obtain the % decrease, we subtracted
this number from 100.
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